Handok Inc. (002390.KS) Stock
Handok Inc.

Company profile
Handok reported revenue of 535.14 billion KRW for fiscal year 2025, up 5.5% from fiscal year 2024. Korea was its largest region in fiscal year 2024, with 97% of revenue. Our analysis of its filings shows revenue growing from 522.74 billion KRW in fiscal year 2023 to 535.14 billion KRW in fiscal year 2025, 1.2% a year on average. Handok reports about 908 full-time employees.
What stands out
- It reported a net loss in each of its last 3 fiscal years, after a profit of 10.68 billion KRW in fiscal year 2022; the loss narrowed from 52.56 billion KRW in fiscal year 2024 to 2.15 billion KRW in fiscal year 2025.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Handok Inc.
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.
Largest shareholders
- Y&S International18.11%
- Young-Jin Kim13.65 %13.65%
- Geum-hee Kim3.253 %3.25%
- Suk-jin Kim2.231 %2.23%
- Young-se Chae1.181 %1.18%
Share of the company, as of September 25, 2026
Leadership
- Young-Jin Kim M.B.A. — Chairman & CEO, 69
- Jeong-yol Cho — President
- Miyeon Kim — President, Director & COO
- Jin Ki Baek — Vice President & Executive Director
In the news
- PAOG CBD RELAX-RX Co-Packing with ALKM And Marketing with USMJ Detailed In Update Scheduled Next Week
- PURA Farmersville Hemp Brand Positioned To Capitalize On President Biden's Environmental Initiative
- PURA Highlights Environmentally Sustainable Hemp Alternatives To Over $1 Trillion In Existing Industrial Products And Services
- PAOG Targets $18 Billion Anxiety And Depression Treatment Market
How much revenue does Handok make?
Handok reported 535.14 billion KRW in revenue for fiscal year 2025, up 5.5% from 507.36 billion KRW in fiscal year 2024.
Where does Handok make most of its revenue?
Korea: 97% of revenue by region in fiscal year 2024, followed by outside of Korea (3%).
What companies are similar to Handok?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Jeil Pharmaceutical Co.,Ltd (271980.KS), Ilyang Pharmaceutical Co.,Ltd (007570.KS), Samsung Pharm. Co., Ltd. (001360.KS), Ahn-Gook Pharmaceutical Co., Ltd. (001540.KQ).
Has Handok made a profit in recent years?
Net income by fiscal year: FY2021, 3.29 billion KRW; FY2022, 10.68 billion KRW; FY2023, a loss of 28.80 billion KRW; FY2024, a loss of 52.56 billion KRW; FY2025, a loss of 2.15 billion KRW. It reported a net loss in 3 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Handok Inc. (002390.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/002390.KS